3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
6
Esophageal Neoplasms
4
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Adenocarcinoma
2
Solid Tumor
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Nasopharyngeal Carcinoma
1
Locally Advanced Gastric Adenocarcinoma
1
Hand-Foot Syndrome
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Fluorouracil
41
Radiotherapy
38
Cisplatin
35
Oxaliplatin
32
Leucovorin
24
Paclitaxel
22
Irinotecan
20
Docetaxel
17
Neoadjuvant Therapy
14
Carboplatin
13
Radiation
12
Capecitabine
12
Surgical Procedures, Operative
10
Cetuximab
8
Biopsy
8
durvalumab
7
Gefitinib
7
Chemotherapy, Adjuvant
7
tremelimumab
6
pembrolizumab
6
Nivolumab
6
Magnetic Resonance Spectroscopy
6
Folfox protocol
6
Taxes
5
Immunohistochemistry
5
Endoscopy
5
Gene Expression Profiling
4
Epirubicin
4
Drug Therapy
4
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma Of Esophagus
×
tegafur-gimeracil-oteracil
×
Clear all
NCT02128243
2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2
Completed
242 enrolled